With its controversial aducanumab approval in hand, Biogen gears up for a quick US rollout
In what will prove to be a controversial decision for years to come, the FDA earlier this week approved Biogen’s aducanumab for Alzheimer’s disease despite some mixed — to say the least — data supporting its use. But Biogen has stayed confident it would secure that nod, and now all the manufacturing and logistics prework the drugmaker did to gear up for launch should spell a quick rollout.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.